Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
gemcitabine + cisplatin + docetaxel
- Development stage
- Phase 2
- Lead developer
- Sanofi
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
A combination chemotherapy regimen comprising gemcitabine, cisplatin, and docetaxel, studied as a first-line treatment for locally advanced or metastatic non-small cell lung cancer (NSCLC). This regimen utilizes three distinct mechanisms of action: gemcitabine acts as a nucleoside analog that inhibits DNA synthesis and ribonucleotide reductase; cisplatin is a platinum-based agent that creates DNA cross-links to induce apoptosis; and docetaxel is a taxane that stabilizes microtubules, leading to mitotic arrest. Sanofi sponsored clinical research, specifically a Phase II trial, to evaluate the efficacy and safety of sequential or concurrent administration of these agents compared to doublet therapies in advanced lung cancer patients.
- Other names
- Gemcitabine/Cisplatin/DocetaxelDocetaxel/Gemcitabine/Cisplatin
02
Targets
DNARNR (Ribonucleotide reductase)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on gemcitabine + cisplatin + docetaxel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on gemcitabine + cisplatin + docetaxel.